EpiCypher and New England Biolabs Enhance Partnership in Epigenomics Innovation

EpiCypher and New England Biolabs Deepen Their Strategic Alliance

In an exciting development for the field of epigenomics, EpiCypher® and New England Biolabs® (NEB®) have broadened their strategic partnership to co-create next-generation research tools aimed at advancing our understanding of gene expression and regulation. This collaboration builds on their successful history, designed to bring innovative technologies to the forefront of epigenetic research and applications.

The partnership effectively combines EpiCypher's expertise in chromatin biology and epigenomic profiling with NEB's established proficiency in enzyme innovation and molecular biology. The goal is clear: to provide high-performance solutions that facilitate deeper and more accurate insights into the complex mechanisms of epigenetic regulation—a vital aspect of molecular biology that influences how genes are expressed. NEB has a proven track record in this area, having developed several novel techniques for studying DNA methylation, chromatin accessibility, and other crucial epigenetic factors.

“As we expand our collaboration, our focus will be on creating groundbreaking genomic tools, kits, and protocols. Some of these innovations are already supported by NIH SBIR funding,” stated the companies in their joint announcement. Among the various tools being developed are methods for CUTRUN, CUTTag, and NiCE-seq, along with new multiomic workflows that include Multiomic CUTRUN and meCUTRUN. These advanced tools leverage NEB's Enzymatic Methyl-seq (EM-seq™) technology to enable researchers to glean critical information from genome studies.

The new partnership will also encompass long-read sequencing applications. EpiCypher's latest launch, the CUTANA® Fiber-seq kit, integrates crucial NEB reagents, significantly expediting its market entry while ensuring top-notch performance in real-world research scenarios.

As part of the expanded agreement, NEB will serve as the distributor for EpiCypher's CUTANA portfolio of genomic products in key international markets, commencing with Germany and the United Kingdom. Additional markets are expected to follow later this year.

Isaac B. Meek, Director of Corporate and Business Development at NEB, highlighted the alignment of values between the two organizations, emphasizing their shared commitment to scientific integrity and the drive for innovation. “Our collaboration with EpiCypher has opened new pathways to enhance our technological offerings and support researchers in their quest to understand complex biological systems,” he said.

“The enhanced partnership with NEB enables us to amplify our global impact,” added Martis Cowles, Ph.D., Chief Business Officer of EpiCypher. “By fusing our assay development prowess with NEB's expertise in enzyme and reagent production, we are poised to deliver insights that may reshape our understanding of gene regulation and disease biology.”

This collaboration is set to significantly impact research in epigenomics, promising to bring forth tools that will facilitate groundbreaking discoveries in gene regulation mechanisms. The robust experience of both companies—EpiCypher's cutting-edge platforms and NEB's extensive product portfolio—positions them ideally to lead the charge in epigenetic research and innovation worldwide.

About EpiCypher

EpiCypher was established to address the growing need for high-quality reagents for chromatin regulation research and to facilitate epigenetics-based drug discovery. The company is at the forefront of chromatin mapping technologies, exemplified by its CUTANA® platform, which encompasses ultra-sensitive CUTRUN, CUTTag, and DNA methylation profiling assays. EpiCypher also provides the largest selection of designer nucleosomes (dNucs) available, alongside high-throughput assays and genomic services.

To learn more about EpiCypher and its revolutionary research technologies, please visit www.epicypher.com.

About New England Biolabs

With over 50 years of dedication to scientific discovery, New England Biolabs (NEB) remains a pioneer in developing innovative products tailored for molecular biology research. Their commitment is reflected in an ever-growing portfolio of tools that support cutting-edge applications in molecular diagnostics and nucleic-acid vaccine development.

For further information about NEB, go to www.neb.com.